Sinopharm, now the China distributor of Merck & Co’s COVID-19 antiviral treatment molnupiravir, said its biotech unit received clinical trial approval from the National Medical Products Administration.
https://www.pharmalive.com/wp-content/uploads/2020/08/China-Sinopharms-potential-COVID-19-vaccine-triggers-antibodies-in-clinical-trials-journal-Reuters-8-14-20.jpeg250370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-01-20 00:37:412023-01-20 10:30:04Sinopharm unit gets OK for clinical trials of mRNA COVID vaccine
